Navigation Links
M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics' MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
Date:8/11/2008

The Study Will Correlate the Results of Rosetta Genomics' MicroRNA-Based CUP Assay With Diagnostic Work Conducted at M.D. Anderson Cancer Center Data on the Company's MicroRNA-Based CUP Assay and its High Sensitivity and Accuracy was Recently Published in the April Issue of Nature Biotechnology

REHOVOT, Israel and JERSEY CITY, New Jersey, August 11 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today the initiation of a clinical validation study with The University of Texas M. D. Anderson Cancer Center (MDACC). The study will focus on Rosetta Genomics' microRNA-based test that identifies the primary site of cancer of unknown primary (CUP). The study will include one hundred patients who are diagnosed with CUP at MDACC, and who meet the eligibility criteria. Rosetta Genomics expects this test to be submitted for regulatory approval in the second half of 2008.

"The initiation of this validation study is an integral part of the commercialization roadmap for our diagnostic tests, as we advance them towards use in a clinical setting," said Amir Avniel, President and CEO of Rosetta Genomics. "We believe the initiation of this study for our CUP assay with a leading cancer research center such as M. D. Anderson attests to the critical unmet need this test addresses." CUP is a heterogeneous group of cancers that constitutes 3-5% of all cancers with a poor median survival of 6-10 months(1). Each year, approximately 70,000 patients in the United States are diagnosed with CUP. A patient is typically diagnosed with CUP only after undergoing a wide range of tests, including various imaging tests such as x-ray, CT, MRI, and PET, which often fail to identify the origin of the cancer.

Presently, the choice of treatment for metastatic cancer is largely dependent on the nature of the primary tumor. Patients with CUP pose a therapeutic dilemma and t
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
2. Fals-Stewart Earns Hazeldens 2007 Dan Anderson Research Award
3. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
4. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
5. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
6. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The Assistance Fund announces the addition of ... assistance for copay to individuals diagnosed with Melanoma. ... of the Melanoma Copay Assistance Program to our portfolio ... director. "With each additional program we are closer to ... no one is denied access to medications due to ...
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... approval of Zarxio (filgrastim-sndz) -- the first biosimilar ... -- points toward growth in the ... Information. The mainstream CMO industry is geared to ... infrastructure to produce major biopharmaceutical products. The healthcare ...
(Date:5/22/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has announced ... Application Dossiers for Oversea Medical device registration and ... to their offering. The Chinese medical ... the most growth potentiality, which is attracting more ... to penetrate such market. It is estimated that ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... Corporation (Nasdaq: DNDN ) today announced that ... Phase 1 clinical trial of D3263 in patients with ... drug candidate designed to target TRPM8 (a transmembrane cation ... The trial is an open-label, dose-escalation study evaluating ...
... strategies for personalized approach to cancer treatmentSEATTLE, April ... subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and ... which utilized RNA interference (RNAi) and bioinformatics to ... that enhance the anti-tumor response to the experimental ...
Cached Medicine Technology:Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 2Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
(Date:5/25/2015)... World Patent Marketing, a vertically integrated ... Little Party Table, a party invention that gives people ... suit their party needs. , "Worldwide indoor and outdoor ... past year. Party Supply Rentals alone are a ... CEO and Creative Director of World Patent Marketing ...
(Date:5/25/2015)... Iowa City, Iowa (PRWEB) May 25, 2015 ... Engineering Excellence awards for design of the ... in Iowa City, Iowa.    The project received a National Recognition ... and an Honor Award from ACEC – Iowa. ... outstanding engineering achievements. , The $50.2 million expansion is ...
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology ... to its Medical Answering Service customers. Through a ... Tunstall now provides a seamless transition between a health ... ensure superior patient satisfaction. , Tunstall is ... million in expanded facilities and the latest telecommunication software ...
(Date:5/24/2015)... Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... patients for concerns about hair loss. Although it is ... clear that there are environmental factors such as metabolism, ... can contribute. Since they offer a comprehensive approach to ... peri and post-menopausal woman, they can help patients find ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... health insurance providers can motivate and sustain member participation in wellness ... ... Louis, MO (PRWEB) November 6, 2008 -- As a strategic partner ... new whitepaper for health insurance companies that need to improve wellness ...
... Long-Lasting Results and Physician Expertise Most Important, ... A new study,conducted by the American Society ... business of sanofi-aventis U.S. LLC, reveals the,influencers ... medical,anti-aging treatments. The study surveyed women ages ...
... 6 Continuing its efforts to,educate, inform, and ... a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... on,Monday, November 10, 2008 at 6:00 PM on ... frank discussion with Joy Loverde, a,nationally known expert ...
... and Healthier for People With,Diabetes and Their Caregivers, ... a time,for love, laughter, and family, usually accompanied by ... temptations may leave some,of the nearly 24 million people ... Last holiday season, dLife helped over 100,000 online,visitors survive ...
... Corporation,(Nasdaq: RGEN ) today reported results for the ... Total revenue for the quarter was,$5,090,000 compared to total ... 2008 ended September 30, 2007. Total revenue was comprised,of ... of Protein A revenue, for the second quarter of ...
... Corporation,(Nasdaq: RGEN ) announced today that the ... evaluate the use of RG2417, an oral formulation ... 2b study is a,multi-center, randomized, double-blind, placebo-controlled clinical ... will receive,either RG2417 or placebo twice daily for ...
Cached Medicine News:Health News:Health and Wellness Incentives 2Health News:New Study Reveals What Women Want When Considering Cosmetic Procedures 2Health News:Health Caring for the Elderly 2Health News:Back By Popular Demand - dLife Holiday Helpline 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 7Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 8Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
... only task-critical information to the operator ... Up to 14 additional computers can ... the facility using a dedicated local ... and administrators can all access the ...
... VerdaSee Patient Bracelet-ID™ provides a solution ... personnel to elopement or unauthorized movement ... issues are a key concern. Certain ... care, Alzheimer's victims, patients with highly ...
... a small radio transmitter combines state-of-the-art ... design. The tag incorporates a tamper ... as the tag is attached to ... electronic Heartbeat® signal every 10 seconds ...
Medicine Products: